HB10857: To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.

Sponsors

• Jake Auchincloss (D, HD-004) · primary sponsor
• H. Morgan Griffith (R, HD-009)

Latest actions

1. October 22, 2026: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2. October 22, 2026: Introduced in House

Common questions

What is HB10857?

HB10857 is a bill in Congress (119th Congress): To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.

What is the status of HB10857?

In committee as of October 22, 2026. Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (October 22, 2026).

Who sponsored HB10857?

Jake Auchincloss (D, HD-004), with 1 co-sponsor.

Where is the official record for HB10857?

On the Congress website: https://www.congress.gov/bill/119th-congress/house-bill/10857